We are live on ! Find out more
ESLA icon

Estrella Immunopharma
ESLA

23 hedge funds and large institutions have $34.5M invested in Estrella Immunopharma in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

5% more funds holding

Funds holding: 22 → 23 (+1)

2% more capital invested

Capital invested by funds: $33.9M → $34.5M (+$575K)

0.63% more ownership

Funds ownership: 57.95% → 58.58% (+0.63%)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
23
Holders Change
+1
Holders Change %
+4.55%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
3
Increased
5
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KIM
Karpus Investment Management
New York
+$226K
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$174K
3
OFG
OTA Financial Group
New York
+$136K
4
CSS
Cubist Systematic Strategies
Connecticut
+$31.5K
5
EC
Elequin Capital
New York
+$24.1K

Top Sellers

Rank Fund Capital Flow
1
PCM
Pinz Capital Management
New York
-$241K
2
SSA
Schonfeld Strategic Advisors
New York
-$113K
3
Goldman Sachs
Goldman Sachs
New York
-$101K
Name Holding Trade Value Shares
Change 		Change in
Stake
KIM
1
Karpus Investment Management
New York
$8.9M +$226K +22,500 +3%
ASM
2
ATW SPAC Management
New York
$3.92M – – –
BFM
3
Boothbay Fund Management
New York
$3.92M – – –
HHGC
4
Hunting Hill Global Capital
New York
$2.91M – – –
CSS
5
Cubist Systematic Strategies
Connecticut
$2.21M +$31.5K +3,131 +1%
Nomura Holdings
6
Nomura Holdings
Japan
$1.98M – – –
CH
7
CVI Holdings
Delaware
$1.77M – – –
Hudson Bay Capital Management
8
Hudson Bay Capital Management
Connecticut
$1.76M – – –
RCM
9
Radcliffe Capital Management
Pennsylvania
$1.01M – – –
Goldman Sachs
10
Goldman Sachs
New York
$971K -$101K -10,070 -9%
PNC Financial Services Group
11
PNC Financial Services Group
Pennsylvania
$939K – – –
WA
12
Whitebox Advisors
Minnesota
$915K – – –
OFG
13
OTA Financial Group
New York
$643K +$136K +13,583 +27%
Citigroup
14
Citigroup
New York
$624K – – –
WRBC
15
W.R. Berkley Corp
Connecticut
$547K – – –
LA
16
Linden Advisors
New York
$418K – – –
Janus Henderson Group
17
Janus Henderson Group
United Kingdom
$350K +$174K +17,335 +100%
LCM
18
Landscape Capital Management
New Jersey
$229K +$20.2K +2,011 +10%
SOA
19
Sea Otter Advisors
Florida
$211K +$211K +21,000 New
Millennium Management
20
Millennium Management
New York
$101K – – –
WAM
21
Weiss Asset Management
Massachusetts
$101K – – –
EC
22
Elequin Capital
New York
$24K +$24.1K +2,400 New
UBS Group
23
UBS Group
Switzerland
$4K +$4.48K +446 New
PCM
24
Pinz Capital Management
New York
– -$241K -24,100 Closed
SSA
25
Schonfeld Strategic Advisors
New York
– -$113K -11,277 Closed

ESLA Hedge Fund Activity: Q3 2022 in Review

23 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q3 2022, worth a combined $34.5M — up 1.7% from $33.9M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ESLA positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Karpus Investment Management, adding an estimated $226K. The largest seller was Pinz Capital Management, exiting entirely with an estimated $241K sold.

  • 23 institutional investors held Estrella Immunopharma (ESLA) as of Q3 2022, up from 22 in Q2 2022.
  • Funds reported $34.5M of Estrella Immunopharma stock for Q3 2022, up 1.7% quarter-over-quarter.
  • 3 funds opened new Estrella Immunopharma positions in Q3 2022 and 2 closed out, a net change of +1 holder.
  • The largest Estrella Immunopharma buyer in Q3 2022 was Karpus Investment Management, an estimated $226K added.
  • The largest Estrella Immunopharma seller in Q3 2022 was Pinz Capital Management, an estimated $241K sold.

Based on aggregated 13F filings for Q3 2022.